Center for Biomarker Research and Precision Medicine, Virginia Commonwealth University, Richmond, VA, USA.
The Molecular Psychiatry Laboratory, The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
Mol Psychiatry. 2020 Jun;25(6):1344-1354. doi: 10.1038/s41380-018-0247-6. Epub 2018 Sep 21.
We present the first large-scale methylome-wide association studies (MWAS) for major depressive disorder (MDD) to identify sites of potential importance for MDD etiology. Using a sequencing-based approach that provides near-complete coverage of all 28 million common CpGs in the human genome, we assay methylation in MDD cases and controls from both blood (N = 1132) and postmortem brain tissues (N = 61 samples from Brodmann Area 10, BA10). The MWAS for blood identified several loci with P ranging from 1.91 × 10 to 4.39 × 10 and a resampling approach showed that the cumulative association was significant (P = 4.03 × 10) with the signal coming from the top 25,000 MWAS markers. Furthermore, a permutation-based analysis showed significant overlap (P = 5.4 × 10) between the MWAS findings in blood and brain (BA10). This overlap was significantly enriched for a number of features including being in eQTLs in blood and the frontal cortex, CpG islands and shores, and exons. The overlapping sites were also enriched for active chromatin states in brain including genic enhancers and active transcription start sites. Furthermore, three loci located in GABBR2, RUFY3, and in an intergenic region on chromosome 2 replicated with the same direction of effect in the second brain tissue (BA25, N = 60) from the same individuals and in two independent brain collections (BA10, N = 81 and 64). GABBR2 inhibits neuronal activity through G protein-coupled second-messenger systems and RUFY3 is implicated in the establishment of neuronal polarity and axon elongation. In conclusion, we identified and replicated methylated loci associated with MDD that are involved in biological functions of likely importance to MDD etiology.
我们进行了首次大规模的重度抑郁症(MDD)全基因组甲基化关联研究(MWAS),以确定 MDD 发病机制的重要潜在位点。使用一种基于测序的方法,该方法可提供人类基因组中所有 2800 万个常见 CpG 的近乎完整覆盖,我们检测了来自血液(病例和对照各 1132 例)和死后脑组织(来自布罗德曼 10 区(BA10)的 61 个样本)的 MDD 病例和对照的甲基化情况。对血液的 MWAS 鉴定出了几个具有 P 值范围从 1.91×10 到 4.39×10 的位点,并且重采样方法表明累积关联具有显著性(P=4.03×10),信号来自前 25000 个 MWAS 标记。此外,基于置换的分析显示血液和大脑(BA10)中的 MWAS 结果之间存在显著重叠(P=5.4×10)。这种重叠在多个特征上显著富集,包括血液和额皮质中的 eQTL、CpG 岛和沿海区以及外显子。重叠位点还在大脑中富含活性染色质状态,包括基因增强子和活跃的转录起始位点。此外,位于 GABBR2、RUFY3 以及染色体 2 上的一个基因间区域的三个位点在来自同一个体的第二个脑组织(BA25,N=60)以及两个独立的脑组织集合(BA10,N=81 和 64)中复制了相同方向的效应。GABBR2 通过 G 蛋白偶联的第二信使系统抑制神经元活性,而 RUFY3 参与神经元极性的建立和轴突伸长。总之,我们鉴定并复制了与 MDD 相关的甲基化位点,这些位点涉及到对 MDD 发病机制具有重要意义的生物学功能。